ZNF713 Knockout cell line (EA.hy 926) – Genotype Verified & Ready-to-use

Red cotton OmniCell bank

10000⁺

Gene Knockout Cell Lines

2000⁺

Luc/EGFP/Cas9 Tool Cell Lines

1000⁺

Wild-type Cell Lines

ZNF713 Knockout cell line (EA.hy 926)

Copy Product Info

Catalog#

YKO-HA210611

Species

Human

Target Cell Line

EA.hy 926

Size

1*10^6

Gene

ZNF713

Storage conditions

Shipped on dry ice; Store in liquid nitrogen

Overview

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZNF713 (zinc finger protein 713) encodes a protein containing C2H2 zinc finger domains, consistent with a potential role in DNA binding and transcriptional regulation. A CGG-repeat expansion within the first intron has been reported to alter ZNF713 expression and has been proposed to be associated with autism spectrum disorder. The specific molecular function of ZNF713 remains incompletely characterized.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

KO Cell Construction Strategy

Adopting Red Cotton CRISPR Gene Editing Designer (www.rc-crispr.com), two sgRNAs targeting the ZNF713 gene are designed to generate a knockout strategy. The two sgRNA sequences are subsequently cloned into the EZ-editor™ vector and introduced into EA.hy 926 cells via electroporation or lentiviral transduction. Single-cell clones are then generated using the limiting dilution method. Genomic DNA from individual clones is subjected to nucleic acid lysis and PCR amplification using the EZ-editor™ Monoclone Genotype Validation Kit (Cat# YK-MV-1000). The edited loci are further verified by Sanger sequencing to confirm the genotype. After secondary validation and quality confirmation, ZNF713 Knockout cell line (EA.hy 926) is expanded and cryopreserved for downstream applications.

Product Overview

ZNF713 Knockout cell line (EA.hy 926)

The ZNF713 Knockout cell line (EA.hy 926) is generated by targeted disruption of the ZNF713 gene in EA.hy 926 cells. This cell line is designed to investigate the role of ZNF713 in cellular function and gene regulation, as well as its potential involvement in disease-related pathways.

KO Cell Line

ZNF713 Knockout cell line (EA.hy 926)

Gene ID

349075

Catalog

YKO-HA210611

Gene Name

ZNF713

Product Category

Knockout(KO) Cell Line

Gene Information

NCBI

Species

Human

Mycoplasma test

Negative

Cell Morphology

Endothelial cells, adherent

Catalog Status

-

Culture method

90%DMEM+10%FBS

Shipping

Cryopreserved Cells shipped in dry ice

Passage ratio

1:2~1:3

Storage Condition

Liquid nitrogen

Quality Control

All KO cell products are tested and confirmed to be free of bacterial, viral, mycoplasma contamination, and other adventitious agents.

Applications

For research use only. Not intended for use in diagnostic, therapeutic, clinical, or other applications.

Key Advantages

Easy to use

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations

High-efficient KO

These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.

Curated cells

Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Quality Control Specifications

1. Bacteria and Fungi Test

None Detected.

2. Mycoplasma test

Negative.

3. Knockout Strategy

Targeted knockout region: EExon 5

Reference Transcript: NM_182633

Frameshift Mutation Strategy

4. STR Authentication

Download STR Report

Intended use

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use

References

More

FAQ

Q1. How to Contact Support if Issues Arise After Receiving the KO Cells?

If any abnormalities are observed after receiving the cells, please provide the following information based on the stage of use and contact us promptly for assistance:

(1) Issues upon delivery: Please provide photos of the cells at the time of receipt along with a brief description of the issue. We will offer after-sales support accordingly.

(2) Issues after thawing or passaging: Please provide microscopic images of the cells before and after thawing/passaging, along with a detailed description of the experimental procedures. Our technical team will provide professional support.

Q2. What Information Is Required When Reporting KO Cell Product Issues?

Q3. How Should the KO cell Product Be Stored Upon Receipt?

Q4. Shipping Method

Q5. Are the Knockout Cell Lines Stable for Passaging? Is Authentication Provided?